I know for adults they've seen a um reduced risk of serious conditions like dementia, Alzheimer's, um heart disease, cancers as well after taking these GLP1s for extended periods of time. And and you mentioned of course that we don't have a lot of science um when it comes to prolonged periods of taking these GLP1s, but is there any science to suggest that as a child if you start these GLP1s, you too can benefit from that. Definitely.And I think that we've actually seen that when kids develop some of these c ...

New study suggests self-employment may reduce the risk of heart disease. https://t.co/pSEZzjwdNr https://t.co/X0gXMgNp98 ...

New study suggests self-employment may reduce the risk of heart disease. https://t.co/7CJi5QwHUb https://t.co/3vFlgnoS3q ...

We are back now with a football legend opening up about his health. Barry Sanders played 10 seasons for the Detroit Lions and cemented his place as one of the greatest running backs of all time. Well, on Father's Day last year, Sanders suffered a heart attack and now he is opening up about his life-changing experience.In a new documentary by Amgen called The Making of a Heart Attack, here's a sneak peek. For me, it wasn't like a real strong pain. It was just like persistent like right in the middle.And that ...

New study suggests self-employment may reduce the risk of heart disease. https://t.co/dYFalcT9CK https://t.co/eH8BYIDcXp ...

Self-Employment Tied To Lower Heart Disease Risk, New Study Finds https://t.co/XhYELINLNZ https://t.co/XhYELINLNZ ...

Self-Employment Linked to Lower Heart Disease Risk https://t.co/Qb20CYI88X https://t.co/Qb20CYI88X ...

Core Insights - Cumberland Pharmaceuticals Inc. presented positive results from the Phase 2 FIGHT DMD trial for ifetroban, a novel oral therapy targeting Duchenne muscular dystrophy (DMD) heart disease, at the PPMD conference, indicating its potential to protect the heart and reduce cardiac damage in DMD patients [1][2][8] Group 1: Trial Results - The 12-month Phase 2 FIGHT DMD trial demonstrated a significant 5.4% improvement in left ventricular ejection fraction (LVEF) in patients treated with high-dose ifetroban compared to a control group [4] - High-dose ifetroban treatment was associated with reduced blood levels of cardiac damage markers (NT-proBNP and cardiac troponin I), while these markers increased in placebo-treated patients, suggesting ifetroban's potential to prevent ongoing cardiac injury [5] - All patients who completed the study opted to continue with the open-label extension, indicating confidence in the treatment [7] Group 2: Pharmacokinetics and Tolerability - The study revealed that DMD patients receiving higher doses of ifetroban achieved similar plasma levels to typical adults without evidence of drug accumulation, supporting the 300 mg daily dosing used in the high-dose group [6] - Ifetroban was well-tolerated with an acceptable pharmacokinetic profile in patients with DMD, despite the higher dosing requirements [6] Group 3: Market Potential and Regulatory Pathway - Ifetroban is positioned to address the leading cause of death in DMD patients, with no approved treatment specifically targeting DMD heart disease, highlighting a critical unmet medical need [9][10] - The company plans to analyze long-term treatment results and engage in discussions with the FDA regarding the regulatory pathway forward based on the trial's encouraging results [10]

Core Insights - Orchestra BioMed Holdings, Inc. presented key clinical insights on AVIM therapy for high-risk hypertension at the CSI 2025 Meeting, emphasizing its potential to address hypertensive heart disease, a significant cardiovascular syndrome affecting an aging population [1][6] Company Overview - Orchestra BioMed is a biomedical innovation company focused on accelerating high-impact technologies through risk-reward sharing partnerships with leading medical device companies [5] - The company’s lead product candidate is AVIM therapy, designed for hypertension, which is a leading risk factor for mortality worldwide [5][8] AVIM Therapy Insights - AVIM therapy is a novel, device-based approach specifically targeting patients with hypertensive heart disease, who are at increased risk for major adverse cardiac events and currently lack sufficient therapeutic options [2][3] - The therapy aims to reduce cardiac preload and modulate autonomic nervous system responses to lower blood pressure and improve cardiovascular function, representing a potential paradigm shift in blood pressure management [3][4] Clinical Data and Studies - Pilot studies have shown that AVIM therapy resulted in net reductions of 8.1 mmHg in 24-hour ambulatory systolic blood pressure and 12.3 mmHg in office systolic blood pressure at six months compared to control patients [10] - The BACKBEAT global pivotal study is currently enrolling patients with uncontrolled hypertension who are indicated for a dual-chamber pacemaker, in collaboration with Medtronic [7][10] Market Opportunity - Hypertensive heart disease affects over 7.7 million patients in the U.S., highlighting a significant market opportunity for AVIM therapy, especially given its recent FDA Breakthrough Device Designation [6][10]

Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDTMay 27, 2025 7:27 AM EDT | Source: Cardiol Therapeutics Inc.Toronto, Ontario--(Newsfile Corp. - May 27, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, announces that the Company's virtual Annual General M ...